Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nezam H Afdhal

Showing results (61-70 of 120) with videos related to

Pageof 12
Sort By:
Transplantation|August 7, 2016
The Optimal Timing of Hepatitis C Therapy in Transplant Eligible Patients With Child B and C Cirrhosis: A Cost-Effectiveness AnalysisElliot B Tapper, Michael S Hughes, Maria Buti, et al.
Journal of Hepatology|May 17, 2005
Prediction of hepatic fibrosis in HIV/HCV co-infected patients using serum fibrosis markers: the SHASTA indexThomas B Kelleher, Shruti H Mehta, Ramakrishnan Bhaskar, et al.
Hepatology (Baltimore, Md.)|July 9, 2009
A phase III study of the safety and efficacy of viramidine versus ribavirin in treatment-naïve patients with chronic hepatitis C: ViSER1 resultsYves Benhamou, Nezam H Afdhal, David R Nelson, et al.
Journal of Clinical Gastroenterology|November 14, 2015
Serum Ammonia is Associated With Transplant-free Survival in Hospitalized Patients With Acutely Decompensated Cirrhosis [corrected]Vilas R Patwardhan, Zhengui G Jiang, Yesenia Risech-Neiman, et al.
Journal of Gastroenterology and Hepatology|March 23, 2011
Ubiquitin-proteasome profiling for enhanced detection of hepatocellular carcinoma in patients with chronic liver diseaseKevin Z Qu, Ke Zhang, Wanlong Ma, et al.
Hepatology (Baltimore, Md.)|March 25, 2006
Progression of fibrosis in hepatitis C with and without schistosomiasis: correlation with serum markers of fibrosisSanaa M Kamal, Bradley Turner, Qi He, et al.
Hepatology (Baltimore, Md.)|July 19, 2012
Hepatitis C virus-specific T-cell-derived transforming growth factor beta is associated with slow hepatic fibrogenesisShaoyong Li, Lianne E M Vriend, Imad A Nasser, et al.
Hepatology Communications|December 18, 2018
A Pathophysiologic Approach Combining Genetics and Insulin Resistance to Predict the Severity of Nonalcoholic Fatty Liver DiseaseChristopher J Danford, Margery A Connelly, Irina Shalaurova, et al.
Hepatology (Baltimore, Md.)|December 26, 2015
Safety and efficacy of ledipasvir/sofosbuvir for the treatment of genotype 1 hepatitis C in subjects aged 65 years or olderSammy Saab, Sarah H Park, Masashi Mizokami, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 29, 2008
Serum proteomics and biomarkers in hepatocellular carcinoma and chronic liver diseaseNoah T Zinkin, Franck Grall, Killimangalam Bhaskar, et al.
Pageof 12

Showing results (61-70 of 120) with videos related to

Sort By:
Pageof 12
Transplantation|August 7, 2016
The Optimal Timing of Hepatitis C Therapy in Transplant Eligible Patients With Child B and C Cirrhosis: A Cost-Effectiveness AnalysisElliot B Tapper, Michael S Hughes, Maria Buti, et al.
Journal of Hepatology|May 17, 2005
Prediction of hepatic fibrosis in HIV/HCV co-infected patients using serum fibrosis markers: the SHASTA indexThomas B Kelleher, Shruti H Mehta, Ramakrishnan Bhaskar, et al.
Hepatology (Baltimore, Md.)|July 9, 2009
A phase III study of the safety and efficacy of viramidine versus ribavirin in treatment-naïve patients with chronic hepatitis C: ViSER1 resultsYves Benhamou, Nezam H Afdhal, David R Nelson, et al.
Journal of Clinical Gastroenterology|November 14, 2015
Serum Ammonia is Associated With Transplant-free Survival in Hospitalized Patients With Acutely Decompensated Cirrhosis [corrected]Vilas R Patwardhan, Zhengui G Jiang, Yesenia Risech-Neiman, et al.
Journal of Gastroenterology and Hepatology|March 23, 2011
Ubiquitin-proteasome profiling for enhanced detection of hepatocellular carcinoma in patients with chronic liver diseaseKevin Z Qu, Ke Zhang, Wanlong Ma, et al.
Hepatology (Baltimore, Md.)|March 25, 2006
Progression of fibrosis in hepatitis C with and without schistosomiasis: correlation with serum markers of fibrosisSanaa M Kamal, Bradley Turner, Qi He, et al.
Hepatology (Baltimore, Md.)|July 19, 2012
Hepatitis C virus-specific T-cell-derived transforming growth factor beta is associated with slow hepatic fibrogenesisShaoyong Li, Lianne E M Vriend, Imad A Nasser, et al.
Hepatology Communications|December 18, 2018
A Pathophysiologic Approach Combining Genetics and Insulin Resistance to Predict the Severity of Nonalcoholic Fatty Liver DiseaseChristopher J Danford, Margery A Connelly, Irina Shalaurova, et al.
Hepatology (Baltimore, Md.)|December 26, 2015
Safety and efficacy of ledipasvir/sofosbuvir for the treatment of genotype 1 hepatitis C in subjects aged 65 years or olderSammy Saab, Sarah H Park, Masashi Mizokami, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 29, 2008
Serum proteomics and biomarkers in hepatocellular carcinoma and chronic liver diseaseNoah T Zinkin, Franck Grall, Killimangalam Bhaskar, et al.
Pageof 12